Pfizer: A Crossroads of Fortune and Risk

The very notion of a ‘blockbuster’ drug, a term so casually bandied about in these times, speaks to a peculiar modern vanity. It implies a triumph over nature, a singular solution to widespread affliction. Yet, as these blockbusters wane, as their protective shields of exclusivity crumble, the company is forced to confront a truth known to all who have observed the cycles of commerce: reliance on a single, or even a handful of, successes is a fragile foundation indeed. Pfizer must, therefore, rebuild its portfolio, not merely with new products, but with a sustained capacity for innovation. This is not a task for accountants or marketers, but for those who possess a vision, a willingness to gamble on the uncertain promise of scientific discovery.








